Ser

Dade Behrings (hsCRP) Tests and BNTM Series Analyzers

C-Reactive Protein (CRP) is an inflammatory marker that has been associated with an increased risk of having a cardiovascular eventeven in the face of normal LDL levelsin several studies. CRP is created by the liver during systemic infection, and is an acute inflammatory marker. While CRP testing has been around for many years, it has only been recently that tests sensitive enough to measure...

Hematology Analyzers Simple, Sophisticated Technology Serving All Patients

Some form of electronic hematology analyzer is found at the center of most clinical laboratories. A blood cell count is usually the first screening test used to assess general health, rule out anemia or infection, and monitor cancer patients during the course of chemotherapy. It is difficult to imagine medical...

Malvern initiates European user group meetings for chemical imaging

WORCESTERSHIRE , England, 21 June 2007, Malvern Instruments hasheld the inaugural meeting in Europe for users of the company'snear infrared chemical imaging (NIR-CI) systems. The one-day event,which took place on 13 June 2007 was hosted by AstraZeneca inMacclesfield, UK. Malvern customers from some of the world's majorpharmaceutical companies joined Malvern's technical and scientificteam...

Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug

PASADENA, Calif.--(BUSINESS WIRE)--Jun 1, 2007 - Arrowhead ResearchCorporation (Nasdaq:ARWR) announced today that interim Phase I datahas been published in the 2007 American Society for ClinicalOncology Proceedings (ASCO) (Abstract ID 32638). The data are froman ongoing Phase I clinical study designed to evaluate the safety,tolerability, and pharmacokinetics of its lead anti-cancer drugcand...

MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations

Data Include Results from Phase 1 Studies with Monoclonal AntibodyTargeting Interleukin-9 (IL-9); Preclinical Data Provide FurtherRationale for IL-9 Inhibition in Developing Potential AsthmaTherapies GAITHERSBURG, Md., May 24, 2007 /PRNewswire-FirstCall/ --MedImmune, Inc. today announced the presentation of datahighlighting recent progress within the company's inflammatorydisease pipelin...

ProtoKinetix's AAGP Dramatically Increases Recovery Rate of Cryopreserved Stem Cells

VANCOUVER, British Columbia--(BUSINESS WIRE)--May 23, 2007 -ProtoKinetix Inc. (OTCBB:PKTX) has just received the results ofstudies conducted by ITTEC Stem, Inc. at the University of Finland.These outstanding results using AAGP(TM) in the cryopreservationprocess for stem cells demonstrate the vital importance of thismolecule in the rapidly expanding stem cell industry. This is thefirst serie...

New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia

--Study Used To Support FDA Approval of SEROQUEL XR-- WILMINGTON, Del., May 22, 2007 /PRNewswire-FirstCall/ --AstraZeneca today announced that two analyses from a large-scalestudy that investigated the efficacy of SEROQUEL XR(TM) (quetiapinefumarate) Extended-Release Tablets, a once-daily medicine for thetreatment of schizophrenia in adult patients, were presented todayat the annual meeti...

Alterations in Intestinal Serotonin in Irritable Bowel Syndrome and Dyspepsia

ROCHESTER, MN, May 21, 2007-- Serotonin is aneurotransmitter that helps regulate intestinal functions. MayoClinic researchers set out to determine the role of serotonin inpatients with IBS and dyspepsia. The study involved 48 females --including individuals with IBS, individuals with dyspepsia,individuals with both IBS and dyspepsia, and healthy volunteers.Biopsies were obtained from the...

MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease

- Numax Achieves Primary Endpoint Among High-Risk Infants VersusCurrent Standard of Care and Shows Reduction of Medically AttendedOutpatient RSV- Related Lower Respiratory Infections - TORONTO, May 08, 2007 /PRNewswire-FirstCall/ -- MedImmune, Inc.today announced positive results from a large prospective trialconducted for prevention of respiratory syncytial virus (RSV). Thetrial compared...

Studies Presented at Neurology Conference Highlight Early Efficacy, Long-Term Tolerability, and High Patient Satisfaction with Betaseron

BOSTON, May 03, 2007 /PRNewswire/ -- Bayer HealthCarePharmaceuticals announced today the results of three clinicalstudies with Betaseron(R) (interferon beta-1b), presented this weekat the American Academy of Neurology's (AAN) 59th Annual Meeting,demonstrating early efficacy, long-term tolerability, and highpatient satisfaction with treatment in patients with relapsingforms of multiple sc...

First of Its Kind Data Show: Immediate Treatment of Early MS Patients with Betaseron Significantly Delayed Permanent Disability

Risk to confirmed EDSS progression reduced by 40 percent comparedto delayed treatment BOSTON, May 01, 2007 /PRNewswire/ -- Bayer HealthCarePharmaceuticals announced today new data, which show that immediateinitiation(1) of Betaseron(R) (interferon beta-1b) treatment inpatients with a first event suggestive of multiple sclerosis (MS)can significantly reduce the risk of permanent neurologic...

Merck Serono Announces Presentation of Phase III Clinical Data on Safinamide in Parkinson’s Disease at the American Academy of Neurology 59th Annual Meeting

GENEVA, Switzerland, April 27, 2007 –Merck Serono S.A. (virt-x: SEO) and its partner NewronPharmaceuticals S.p.A. (SWX: NWRN) announced today that ProfessorFabrizio Stocchi, MD, PhD, will present the results of the firstPhase III trial of safinamide as an adjunctive treatment todopamine agonists (DA) in early Parkinson’s disease (PD)patien...

Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting

Novel Systems May Provide Cancer Patients With Improved Potentialto Battle Their Disease PASADENA, Calif., April 16, 2007 /PRNewswire-FirstCall/ --Arrowhead Research Corporation announced today that two of itsmajority-owned subsidiaries, Insert Therapeutics Inc. and CalandoPharmaceuticals Inc., are presenting data at the 2007 AmericanAssociation for Cancer Research (AACR) Annual Meeting....

Poster on Cyclosert Drug Delivery Presented at AACR Meeting

Novel System May Provide Cancer Patients With Improved Potential toBattle Their Disease PASADENA, Calif., April 16, 2007 /PRNewswire/ -- InsertTherapeutics, Inc., a majority-owned subsidiary of ArrowheadResearch Corporation announced today its novel delivery systemcalled Cyclosert(TM) will be featured in a poster presentation atthe 2007 American Association for Cancer Research (AACR) Annu...

Icagen Terminates Phase III ASSERT Study

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Apr 3, 2007 -Icagen, Inc. (NASDAQ: ICGN) announced today that following aplanned meeting of the independent Data Monitoring Committee("DMC") of the Company's ASSERT trial of senicapoc (formerlyICA-17043) for the treatment of sickle cell disease in adults, theDMC recommended that the trial be terminated because of the lowprobability of achieving...

Large Study Shows that Presence of Neutralizing Antibodies Did Not Predict Clinical Response to Betaseron Treatment

WAYNE, N.J., April 02, 2007 /PRNewswire/ -- Berlex, Inc., a U.S.affiliate of Bayer Schering Pharma AG, Germany, announced today theresults of a retrospective study demonstrating that the presence ofneutralizing antibodies (NAbs) that can develop in response toBetaseron(R) (interferon beta-1b) therapy did not predict clinicalresponse in patients with multiple sclerosis (MS).(1) The studyl...

Data on Telavancin and Micafungin Hold Promise of New Therapeutic Options in Fight Against Serious Infectious Disease

- Studies Reinforce Astellas Commitment to Overcoming CriticalShortage of New Antimicrobial Agents MUNICH, Germany, April 02, 2007 /PRNewswire/ --Study resultspresented at the 17th European Congress of Clinical Microbiologyand Infectious Diseases (ECCMID) show that the antibiotictelavancin, and the antifungal micafungin, both have the potentialto meet a significant unmet need in th...

Dharma Therapeutics Shows IDDS Is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in Their Phase 2 Clinical Trial

Iontophoretic Drug Delivery System, dermal patch and a directcurrent power source with lidocaine and epinephrine (IDDS) SEATTLE, March 20, 2007 /PRNewswire/ -- Dharma Therapeutics,Inc., ("Dharma") Seattle, WA, a transdermal drug delivery companyand wholly owned subsidiary of Transcutaneous Technologies, Inc.("TTI"), Tokyo, Japan announced that its active transdermaldelivery te...

Seroquel Sustained Release Schizophrenia Data Presented at ECP Congress in Madrid

LONDON, March 18, 2007-AstraZeneca today announced clinicaltrial data for Seroquel sustained release formulation (quetiapinefumarate sustained release), at the European Congress of Psychiatry(ECP) in Madrid. The data demonstrated that the SEROQUEL®sustained release formulation (quetiapine fumarate sustainedrelease), administered once daily, significantly improved symptomsassociated w...

Hollis-Eden Announces Cancellation of Acute Radiation Syndrome RFP by Department of Health and Human Services

SAN DIEGO--(BUSINESS WIRE)--Mar 8, 2007 - Hollis-EdenPharmaceuticals, Inc. (NASDAQ:HEPH) today announced that it wasinformed late Wednesday, March 07, 2007, by the Department ofHealth & Human Services (HHS) that NEUMUNE(R), the Company'sproduct candidate for the treatment of Acute Radiation Syndrome(ARS) was found technically unacceptable and was no longer in thecompetitive range for th...